This portfolio constitutes a unique opportunity for buyers to acquire technology that will enable them to provide phlebotomy needles that are safe for both the patient and the phlebotomist. Alternatively, the patent portfolio can be leveraged to support a broad industry licensing program. The patent portfolio describes superior technology for solving the largely unaddressed problem of ensuring proper placement of the needle in the vein.
Tangible IP is the leader in the sale and acquisition of high-quality patents.
Mr. Carbonneau will speak at the annual Utah Bar IP Summit on February 24, 2023.